As the increasing amount of evidence showing the pathological roles of such targets as CD19, IL-6, C5 complement, CGRP, and CD20 in the modulating of cerebral ischemia severity in clinical reports or pre-clinical studies [93,94,95,96,97], we believe these currently available antibody-based drugs for different neurological disorders could soon been evaluated and re-purposed as an effective antibody drug for stroke treatment in clinic. The gene discussed is IL6; the disease is Stroke.